AstraZeneca PLC (AZN)

業務介紹

阿斯利康有限公司（AstraZeneca PLC）是一家生物製藥公司，專注於處方藥品的發現、研發、製造和商業化。其市場產品包括用於腫瘤學的Calquence、Enhertu、Faslodex、Imfinzi、Iressa、Koselugo、Lumoxiti、Lynparza、Orpathys、Tagrisso和Zoladex；用於心血管、腎臟和代謝疾病的Brilinta/Brilique、Bydureon/Byetta、BCise、Byetta、Crestor、Evrenzo、Farxiga/Forxiga、Komboglyze/Kombiglyze XR、Lokelma、Onglyza、Qtern和Xigduo/Xigduo XR；用於呼吸和免疫學的Bevespi Aerosphere、Breztri Aerosphere、Daliresp/Daxas、Duaklir Genuair、Fasenra、Pulmicort、Saphnelo、Symbicort和Tudorza/Eklira/Bretaris；以及用於罕見疾病的Andexxa/Ondexxya、Kanuma、Soliris、Strensiq和Ultomiris。該公司的市場產品還包括用於呼吸道合胞病毒的Synagis；用於流感的Fluenz Tetra/FluMist Quadrivalent；用於精神分裂症和躁鬱症的Seroquel IR/Seroquel XR；用於胃腸病學的Nexium和Losec/Prilosec；以及用於新冠病毒的Vaxzevria和Evusheld。該公司通過在英國、歐洲其他地區、美洲、亞洲、非洲和大洋洲的分銷商和當地代表辦事處為基層醫療和專科醫生提供服務。該公司與Regeneron Pharmaceuticals, Inc.達成合作協議，共同研究、開發和商業化肥胖症的小分子藥物；與Neurimmune AG合作開發和商業化NI006；與Ionis Pharmaceuticals, Inc.合作開發eplontersen，一種針對肝臟的反義治療，目前正在進行第三期臨床試驗，用於治療甲狀腺激素運輸蛋白淀粉樣變性；與Proteros Biostructures GmbH合作共同發現治療血液系統腫瘤的新型小分子藥物；與Sierra Oncology, Inc.合作開發和商業化AZD5153。該公司前身為Zeneca Group PLC，於1999年4月改名為阿斯利康有限公司。阿斯利康有限公司成立於1992年，總部位於英國劍橋。

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

公司網址

https://www.astrazeneca.com